IP Library Granted Patent US 12,465,698
Granted Patent B2
US 12,465,698 · App. 17/139,079 · Granted Nov 11, 2025

Devices and methods for delivering powdered agents

Inventors: Andrew Pic (Northboro, MA); Laurie Lehtinen (Boylston, MA); Collin Murray (Bolton, MA); Nicholas Seagrave (Dudley, MA)
Assignee: Boston Scientific Scimed, Inc.
A61M5/31596A61M5/19A61M5/3129A61M2202/064
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,465,698
App. No.
17/139,079
Granted
Nov 11, 2025
Kind
B2
Abstract

A device for delivering an agent may comprise a chamber for receiving agent through an agent inlet; and a body received within the chamber. The body may be movable in first and second directions along a longitudinal axis of the chamber. In a first configuration of the body, an amount of the agent may flow into the chamber via the agent inlet. In a second configuration of the body, the agent is prevented from flowing into the chamber via the agent inlet. When the body is transitioned from the first configuration to the second configuration, the amount of the agent may be moved from a first position along the longitudinal axis of the chamber to a second position along the longitudinal axis of the chamber.

Claims (41)

1 . A device for delivering an agent, comprising

an outlet;

a fluid inlet for receiving a fluid, and in fluid communication with the outlet;

a chamber for receiving the agent through an agent inlet, and in fluid communication with the outlet; and

a body received within the chamber, wherein the body is movable in first and second directions along a longitudinal axis of the chamber;

wherein, in a first configuration of the body, a plurality of particles of the agent flows into the chamber via the agent inlet, wherein, in a second configuration of the body, the agent is prevented from flowing into the chamber via the agent inlet, and wherein, when the body is transitioned from the first configuration to the second configuration, the plurality of particles of the agent is moved from a first position along the longitudinal axis of the chamber to a second position along the longitudinal axis of the chamber; and

wherein, when in the first configuration, the body is positioned to obstruct the plurality of particles received in the chamber from moving towards the fluid inlet, when transitioning from the first configuration towards the second configuration the body is positioned relative to the chamber such that only a first amount of the fluid from the fluid inlet is delivered via the outlet prior to delivering the plurality of particles of the agent from the chamber when the body arrives to the second configuration, and when in the second configuration, the body is repositioned to unobstruct the plurality of particles from moving towards the fluid inlet via gravity such that a mixture of a second amount of the fluid from the fluid inlet and the plurality of particles of the agent from the chamber is generated inside the device after delivering the first amount of the fluid and prior to the mixture exiting the outlet.

2 . The device of claim 1 , wherein, when the body is in the second configuration, the second amount of the fluid flows into the outlet via the fluid inlet in combination with the plurality of particles of the agent.

3 . The device of claim 2 , wherein the fluid inlet is located between (a) the outlet for delivering the second amount of the fluid combined with the plurality of particles of the agent from the chamber and (b) the agent inlet.

4 . The device of claim 1 , further comprising an actuator coupled to the body, wherein the body transitions from the first configuration to the second configuration due to a force applied to the body in response to actuation of the actuator.

5 . The device of claim 1 , further comprising a source of the agent, wherein the source is coupled to the chamber.

6 . The device of claim 1 , wherein the chamber is a first chamber, further comprising a second chamber, wherein the body defines a body opening, wherein, in the first configuration, the body opening is in fluid communication with the agent inlet, and wherein, in the second configuration, the body opening is in not in fluid communication with the agent inlet and is in fluid communication with a chamber opening between the first chamber and the second chamber.

7 . The device of claim 6 , wherein the body is connected to an arm via a hinge.

8 . The device of claim 7 , wherein the arm is connected to a trigger, wherein depressing the trigger causes the arm to pivot and causes the body to move in the first direction.

9 . The device of claim 1 , wherein the device is configured to deliver:

the mixture of the second amount of the fluid and the plurality of particles of the agent when the body is in the second configuration.

10 . The device of claim 1 , further comprising an actuator that is configured to transition the body to each of the first configuration and the second configuration upon a single actuation.

11 . The device of claim 10 , wherein, in response to the single actuation, the actuator is configured to release (1) the first amount of the fluid when transitioning the body from the first configuration towards the second configuration and (2) the mixture when the body is in the second configuration.

12 . The device of claim 11 , wherein, in response to ceasing the single actuation, the actuator is configured to transition the body from the second configuration to a final configuration and terminate release of the mixture through the outlet.

13 . The device of claim 12 , wherein in the final configuration, the body is not positioned in the first configuration, is incapable of delivering any fluid from the device, and blocks the plurality of particles of the agent from flowing into the chamber via the agent inlet.

14 . A device for delivering an agent, comprising

an outlet;

a fluid inlet in fluid communication with the outlet;

a chamber in fluid communication with the agent in a first configuration and the outlet in a second configuration; and

a body that is configured to move relative to the chamber between the first configuration and the second configuration;

wherein, in the first configuration, the body is positioned relative to the chamber such that the body is configured to receive the agent, and in the second configuration, the body is positioned relative to the chamber such that the body is configured to release the agent;

wherein the body is positioned relative to the chamber to obstruct the agent stored in the chamber from moving towards the fluid inlet when in the first configuration, and the body is positioned such that only a first amount of a fluid from the fluid inlet without the agent is delivered via the outlet when the body is moved from the first configuration towards the second configuration, and the body is repositioned relative to the chamber to unobstruct the agent from moving towards the fluid inlet via gravity such that a mixture of a second amount of the fluid from the fluid inlet with the agent from the chamber is generated inside the device when the body is in the second configuration and prior to the mixture exiting the outlet.

15 . The device of claim 14 , wherein the body includes a channel having a longitudinal length that extends through an entirety of the body, and the channel is configured to receive the agent when the body is in the first configuration and release the agent when the body is in the second configuration.

16 . A device for delivering an agent, comprising:

an outlet;

a fluid inlet in fluid communication with the outlet; and

a body that is movable relative to a chamber for selectively receiving the agent;

wherein the body is configured to be transitioned from a first configuration towards a second configuration, such that:

in the first configuration the body is positioned relative to the chamber to block the agent from exiting the chamber and moving towards the fluid inlet;

when transitioning from the first configuration towards the second configuration the body is positioned such that only a first amount of a fluid from the fluid inlet is deliverable to the outlet without the agent; and

upon arriving to the second configuration the body is repositioned relative to the chamber to release the agent received within the chamber towards the fluid inlet via gravity, such that a mixture of a second amount of the fluid from the fluid inlet and the agent from the chamber is created inside the device after delivering the first amount of the fluid to the outlet and prior to the mixture exiting the outlet.

17 . The device of claim 16 , further comprising an actuator that is configured to transition the body between the first configuration, the second configuration, and a final configuration;

wherein, upon an actuation, the actuator is configured to release the first amount of the fluid without the agent and position the body relative to the chamber to receive the agent when transitioning the body to the first configuration.

18 . The device of claim 17 , wherein, upon the actuation, the actuator is configured to position the body relative to the chamber to release the mixture of the second amount of the fluid with the agent when the body is in the second configuration.

19 . The device of claim 18 , wherein, upon ceasing the actuation, the actuator is configured to terminate release of the mixture of the second amount of the fluid with the agent and position the body relative to the chamber to block receipt of the agent within the body when transitioning the body from the second configuration to the final configuration.

20 . The device of claim 19 , wherein in the final configuration, the body is not positioned in the first configuration or the second configuration, is incapable of delivering any fluid from the device, and blocks additional agent from flowing into the chamber.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2020
From: PIC, ANDREW; LEHTINEN, LAURIE; MURRAY, COLLIN; SEAGRAVE, NICHOLAS
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 054784/0198 →
Continuity (2)
Provisional Application 62957519 · Jan 6, 2020
Related Publication 20210205543A1 · Jul 8, 2021
References Cited (185)
US 471854A · Howard · 1892 [cited by applicant]
US 881238A · Hasbrouck · 1908 [cited by applicant]
US 1145520A · Smith · 1915 [cited by applicant]
US 1599959A · Buheiji · 1926 [cited by applicant]
US 1732566A · McKendrick · 1929 [cited by applicant]
US 2151418A · Bolté · 1939 [cited by applicant]
US 2185927A · Shelanski · 1940 [cited by applicant]
US 2478715A · Schmitt · 1949 [cited by applicant]
US 2623519A · Cohen · 1952 [cited by applicant]
US 3402712A · Eisenhand · 1968 [cited by examiner]
US 3602398A · Pollak · 1971 [cited by examiner]
US 3669113A · Altounyan et al. · 1972 [cited by applicant]
US 3797709A · Ivanovich · 1974 [cited by applicant]
US 3940061A · Gimple et al. · 1976 [cited by applicant]
US 4184258A · Barrington et al. · 1980 [cited by applicant]
US 4427450A · Kostansek · 1984 [cited by applicant]
US 4457329A · Werley et al. · 1984 [cited by applicant]
US 4673395A · Phillips · 1987 [cited by applicant]
US 4806167A · Raythatha · 1989 [cited by applicant]
US 5215221A · Dirksing · 1993 [cited by applicant]
US 5231983A · Matson et al. · 1993 [cited by applicant]
US 5273531A · Knopfler · 1993 [cited by applicant]
US 5312331A · Kneopfler · 1994 [cited by applicant]
US 5312333A · Churinetz et al. · 1994 [cited by applicant]
US 5366122A · Guentert et al. · 1994 [cited by applicant]
US 5376079A · Holm · 1994 [cited by applicant]
US 5445612A · Terakura et al. · 1995 [cited by applicant]
US 5470311A · Setterstrom et al. · 1995 [cited by applicant]
US 5884621A · Matsugi et al. · 1999 [cited by applicant]
US 5951531A · Ferdman et al. · 1999 [cited by applicant]
US 6003512A · Gerde · 1999 [cited by applicant]
US 6484750B1 · Foos et al. · 2002 [cited by applicant]
US 6554022B2 · Wakeman · 2003 [cited by applicant]
US 6589087B2 · Mackal et al. · 2003 [cited by applicant]
US 6684917B2 · Zhu et al. · 2004 [cited by applicant]
US 6708712B2 · Wakeman · 2004 [cited by applicant]
US 6716190B1 · Glines et al. · 2004 [cited by applicant]
US 6799571B1 · Hughes et al. · 2004 [cited by applicant]
US 7178547B2 · Mackal · 2007 [cited by applicant]
US 7311270B2 · Kapila · 2007 [cited by applicant]
US 7334598B1 · Hollars · 2008 [cited by applicant]
US 7361300B2 · Kelly et al. · 2008 [cited by applicant]
US 7427607B2 · Suzuki · 2008 [cited by applicant]
US 7455248B2 · Kablik et al. · 2008 [cited by applicant]
US 7461649B2 · Gamard et al. · 2008 [cited by applicant]
US 7544177B2 · Gertner · 2009 [cited by applicant]
US 7563299B2 · Baptista da Costa et al. · 2009 [cited by applicant]
US 7673647B2 · Mackal · 2010 [cited by applicant]
US 7841338B2 · Dunne et al. · 2010 [cited by applicant]
US 7892205B2 · Palasis et al. · 2011 [cited by applicant]
US 7921874B2 · Tekulve et al. · 2011 [cited by applicant]
US 8037880B2 · Zhu et al. · 2011 [cited by applicant]
US 8097071B2 · Burgess et al. · 2012 [cited by applicant]
US 8118777B2 · Ducharme et al. · 2012 [cited by applicant]
US 8269058B2 · McCarthy et al. · 2012 [cited by applicant]
US 8313474B2 · Campbell et al. · 2012 [cited by applicant]
US 8360276B2 · Rogier et al. · 2013 [cited by applicant]
US 8361054B2 · Ducharme et al. · 2013 [cited by applicant]
US 8496189B2 · Lomond et al. · 2013 [cited by applicant]
US 8673065B2 · Burgess et al. · 2014 [cited by applicant]
US 8721582B2 · Ji · 2014 [cited by applicant]
US 8728032B2 · Ducharme et al. · 2014 [cited by applicant]
US 8741335B2 · McCarthy · 2014 [cited by applicant]
US 8827980B2 · Ji · 2014 [cited by applicant]
US 8910627B2 · Iwatschenko et al. · 2014 [cited by applicant]
US 8951565B2 · McCarthy · 2015 [cited by applicant]
US 9028437B2 · Ott et al. · 2015 [cited by applicant]
US 9089658B2 · Dunne et al. · 2015 [cited by applicant]
US 9101744B2 · Ducharme · 2015 [cited by applicant]
US 9107668B2 · Melsheimer et al. · 2015 [cited by applicant]
US 9132206B2 · McCarthy · 2015 [cited by applicant]
US 9204957B2 · Gregory et al. · 2015 [cited by applicant]
US 9205170B2 · Lucchesi et al. · 2015 [cited by applicant]
US 9205207B2 · Ji · 2015 [cited by applicant]
US 9205240B2 · Greenhalgh et al. · 2015 [cited by applicant]
US 9308584B2 · Burgess et al. · 2016 [cited by applicant]
US 9310812B2 · Costle et al. · 2016 [cited by applicant]
US 9375533B2 · Ducharme et al. · 2016 [cited by applicant]
US 9492646B2 · Hoogenakker et al. · 2016 [cited by applicant]
US 9517976B2 · Mackal · 2016 [cited by applicant]
US 9545490B2 · Iwatschenko et al. · 2017 [cited by applicant]
US 9555185B2 · Foster et al. · 2017 [cited by applicant]
US 9629966B2 · Ji · 2017 [cited by applicant]
US 9636470B2 · Pohlmann et al. · 2017 [cited by applicant]
US 9707359B2 · Kubo · 2017 [cited by applicant]
US 9713682B2 · Eistetter et al. · 2017 [cited by applicant]
US 9717897B2 · Rogier · 2017 [cited by applicant]
US 9821084B2 · Diegelmann et al. · 2017 [cited by applicant]
US 9839772B2 · Ducharme · 2017 [cited by applicant]
US 9839774B2 · Bonaldo · 2017 [cited by applicant]
US 9846439B2 · Carman et al. · 2017 [cited by applicant]
US 9867931B2 · Gittard · 2018 [cited by applicant]
US 9976660B2 · Stanton et al. · 2018 [cited by applicant]
US 10004690B2 · Lee et al. · 2018 [cited by applicant]
US 10010705B2 · Greenhalgh et al. · 2018 [cited by applicant]
US 10017231B2 · Fawcett, Jr. · 2018 [cited by applicant]
US 10036617B2 · Mackal · 2018 [cited by applicant]
US 10065004B2 · Eder et al. · 2018 [cited by applicant]
US 10173019B2 · Kaufmann et al. · 2019 [cited by applicant]
US 10384049B2 · Stanton et al. · 2019 [cited by applicant]
US 10463811B2 · Lee et al. · 2019 [cited by applicant]
US 10507293B2 · Goodman et al. · 2019 [cited by applicant]
US 10646706B2 · Rogier · 2020 [cited by applicant]
US 10730595B2 · Fawcett · 2020 [cited by applicant]
US 10751523B2 · Rogier · 2020 [cited by applicant]
US 10806853B2 · Gittard · 2020 [cited by applicant]
US 10850814B2 · Fawcett · 2020 [cited by applicant]
US 10994818B2 · Hernandez · 2021 [cited by applicant]
US 20040107963A1 · Finlay et al. · 2004 [cited by applicant]
US 20040249359A1 · Palasis et al. · 2004 [cited by applicant]
US 20050121025A1 · Gamard et al. · 2005 [cited by applicant]
US 20050147656A1 · McCarthy et al. · 2005 [cited by applicant]
US 20050220721A1 · Kablik et al. · 2005 [cited by applicant]
US 20060004314A1 · McCarthy et al. · 2006 [cited by applicant]
US 20060213514A1 · Price et al. · 2006 [cited by applicant]
US 20070056586A1 · Price et al. · 2007 [cited by applicant]
US 20070066920A1 · Hopman et al. · 2007 [cited by applicant]
US 20070066924A1 · Hopman et al. · 2007 [cited by applicant]
US 20070082023A1 · Hopman et al. · 2007 [cited by applicant]
US 20070083137A1 · Hopman et al. · 2007 [cited by applicant]
US 20070125375A1 · Finlay et al. · 2007 [cited by applicant]
US 20070151560A1 · Price et al. · 2007 [cited by applicant]
US 20070199824A1 · Hoerr et al. · 2007 [cited by applicant]
US 20070213660A1 · Richards et al. · 2007 [cited by applicant]
US 20080021374A1 · Kawata · 2008 [cited by applicant]
US 20080287907A1 · Gregory et al. · 2008 [cited by applicant]
US 20090101144A1 · Gamard et al. · 2009 [cited by applicant]
US 20090155342A1 · Diegemann et al. · 2009 [cited by applicant]
US 20090281486A1 · Ducharme · 2009 [cited by applicant]
US 20100121261A1 · Kablik et al. · 2010 [cited by applicant]
US 20100305505A1 · Ducharme et al. · 2010 [cited by applicant]
US 20110073200A1 · Overvaag et al. · 2011 [cited by applicant]
US 20110274726A1 · Guo et al. · 2011 [cited by applicant]
US 20110308516A1 · Price et al. · 2011 [cited by applicant]
US 20140271491A1 · Gittard et al. · 2014 [cited by applicant]
US 20150017601A1 · Fish · 2015 [cited by examiner]
US 20150094649A1 · Gittard · 2015 [cited by applicant]
US 20150125513A1 · McCarthy · 2015 [cited by applicant]
US 20160375202A1 · Goodman et al. · 2016 [cited by applicant]
US 20170106181A1 · Bonaldo et al. · 2017 [cited by applicant]
US 20170232141A1 · Surti et al. · 2017 [cited by applicant]
US 20170252479A1 · Ji et al. · 2017 [cited by applicant]
US 20170296760A1 · Lee et al. · 2017 [cited by applicant]
US 20180099088A1 · Gittard · 2018 [cited by applicant]
US 20180193574A1 · Smith et al. · 2018 [cited by applicant]
US 20180214160A1 · Hoskins et al. · 2018 [cited by applicant]
US 20180339144A1 · Greenhalgh et al. · 2018 [cited by applicant]
US 20190134366A1 · Erez et al. · 2019 [cited by applicant]
US 20190217315A1 · Maguire et al. · 2019 [cited by applicant]
US 20190232030A1 · Pic et al. · 2019 [cited by applicant]
US 20210024187A1 · Fawcett et al. · 2021 [cited by applicant]
US 20210069485A1 · Rogier · 2021 [cited by applicant]
CN 101401956B · 2012 [cited by applicant]
CN 108289789A · 2018 [cited by applicant]
CN 108472666A · 2018 [cited by applicant]
DE 60215438T2 · 2007 [cited by applicant]
EP 3052168B1 · 2019 [cited by applicant]
EP 4275727A2 · 2023 [cited by applicant]
JP H07118305A · 1995 [cited by applicant]
WO 03013552A1 · 2003 [cited by applicant]
WO 2004066806A2 · 2004 [cited by applicant]
WO 2005062896A2 · 2005 [cited by applicant]
WO 2006071649A2 · 2006 [cited by applicant]
WO 2006088912A2 · 2006 [cited by applicant]
WO 2008033462A2 · 2008 [cited by applicant]
WO 2009061409A1 · 2009 [cited by applicant]
WO 2015050814A1 · 2015 [cited by applicant]
WO 2018157772A1 · 2018 [cited by applicant]
Bridevaux, Pierre-Olivier, et al. “Short-term safety of thoracoscopic talc pleurodesis for recurrent primary spontaneous pneumothorax: a prospective European multicentre study.” European Respiratory Journal 38.4 (2011):… [cited by applicant]
Giday, Samuel, et al. “Safety analysis of a hemostatic powder in a porcine model of acute severe gastric bleeding.” Digestive diseases and sciences 58.12 (2013): 3422-3428. [cited by applicant]
Giday, Samuel A., et al. “A long-term randomized controlled trial of a novel nanopowder hemostatic agent for control of severe upper gastrointestinal bleeding in a porcine model.” Gastrointestinal Endoscopy 69.5 (2009):… [cited by applicant]
Giday, S. A., et al. “Long-term randomized controlled trial of a novel nanopowder hemostatic agent (TC-325) for control of severe arterial upper gastrointestinal bleeding in a porcine model.” Endoscopy 43.04 (2011): 296… [cited by applicant]
Regalia, Kristen, et al. “Hemospray in Gastrointestinal Bleeding.” Practical Gastroenterology. Endoscopy: Opening New Eyes, ser. 8, May 2014, pp. 13-24. 8. [cited by applicant]
Cook Medical. Hemospray Endoscopic Hemostat, Cook, 2014. (7 pages, in English). [cited by applicant]
“Hemospray Clinical Experience Shows Efficacy of a New Hemostasis Modality—v1”, Cook Medical, 2012. [cited by applicant]
“Hemospray Clinical Experience Shows Efficacy of a New Hemostasis Modality—v2”, Cook Medical, 2013. [cited by applicant]
“Hemospray Clinical Experience Shows Efficacy of a New Hemostasis Modality—v3”, Cook Medical, 2014. [cited by applicant]
Aslanian, Harry R., and Loren Laine. “Hemostatic powder spray for GI bleeding.” Gastrointestinal endoscopy 77.3 (2013): 508-510. [cited by applicant]
Giday, S. A., et al. “Long-term randomized controlled trial of a novel nanopowder hemostatic agent (TC-325) for control of severe arterial upper gastrointestinal bleeding in a porcine model.” Endoscopy 43.04 (2011): 296… [cited by applicant]
RETSCH GmbH Haan. Sieve Analysis: Taking a Close Look at Quality, An Expert Guide to Particle Size Analysis. 2015. (56 pages, in English). [cited by applicant]
Micromeritics. Density Analysis, 2001. (6 pages, in English). [cited by applicant]
Micromeritics. “Application Note: Bulk and Skeletal Density Computations for the AutoPore.” May 2012. (3 pages, in English). [cited by applicant]
Arefnia, Ali, et al. “Comparative Study on the Effect of Tire-Derived Aggregate on Specific Gravity of Kaolin.” Electronic Journal of Geotechnical Engineering 18 (2013): 335-44. [cited by applicant]
Kesavan, Jana, et al. “Density Measurements of Materials Used in Aerosol Studies”. Edgewood Chemical Biological Center Aberdeen Proving Ground MD, 2000. [cited by applicant]
International Search Report and Written Opinion issued on May 31, 2021 in counterpart International Patent Application No. PCT/US2020/067626 (21 pages, in English). [cited by applicant]